Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2026-07-13 16:00:02 ET · period of report 2026-07-09 · accession 0001193125-26-301996 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-07-13 16:00 | 2026-07-09+ | AMLX | Mazzariello Gina | CLO | S - Sale | $17.96 | -30.0K | 179.1K | -14% | -$538.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-09 | S | D | 15,000 | $18.32 | 194,090 | D | — | — | (F1) The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2026-07-10 | S | D | 15,000 | $17.61 | 179,090 | D | — | — | (F1) The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |